Sarepta Investors Buckle Up for Pfizer’s DMD Gene Therapy Update

(Bloomberg) -- A fresh look at how a handful of patients are faring on Pfizer Inc.’s gene therapy for Duchenne muscular dystrophy will be key for investors in competitor Sarepta Therapeutics Inc.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.